Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Bought by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC raised its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 46.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,202 shares of the biotechnology company’s stock after acquiring an additional 2,274 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Enanta Pharmaceuticals were worth $41,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of ENTA. China Universal Asset Management Co. Ltd. acquired a new position in Enanta Pharmaceuticals in the fourth quarter valued at approximately $26,000. Intech Investment Management LLC acquired a new position in Enanta Pharmaceuticals in the fourth quarter valued at approximately $58,000. Wells Fargo & Company MN lifted its holdings in Enanta Pharmaceuticals by 69.6% in the fourth quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company’s stock valued at $91,000 after acquiring an additional 6,518 shares during the period. AlphaQuest LLC increased its position in shares of Enanta Pharmaceuticals by 16.4% in the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 3,137 shares in the last quarter. Finally, Bank of Montreal Can purchased a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at approximately $183,000. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA opened at $5.23 on Wednesday. Enanta Pharmaceuticals, Inc. has a one year low of $4.09 and a one year high of $17.24. The stock has a market capitalization of $111.57 million, a price-to-earnings ratio of -1.06 and a beta of 0.81. The stock has a 50 day moving average price of $5.59 and a 200 day moving average price of $6.75.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($1.04) by ($0.02). Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. The firm had revenue of $14.93 million for the quarter, compared to analysts’ expectations of $15.96 million. On average, analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ENTA. StockNews.com upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 19th. JMP Securities restated a “market outperform” rating and issued a $21.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. Finally, HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Enanta Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.